High-priority alert based on source significance and keyword relevance.
Context
What happened: Intellia Therapeutics (NTLA) held an investor event on Lonvo-z, its onetime gene editing candidate for hereditary angioedema, at the 2026 ACAAI Scientific Meeting in Phoenix, alongside a press release on 7 congress presentations.
Key numbers: Event dated November 12, 2026, 10:00 AM EST. 7 presentations at the congress.
Why it matters: The call covered Lonvo-z clinical data and commercial launch preparations, with company executives and commercial leadership presenting to investors and research analysts.
What changed
Intellia Therapeutics (NTLA) held an investor event on Lonvo-z, its onetime gene editing candidate for hereditary angioedema, at the 2026 ACAAI Scientific Meeting in Phoenix, alongside a press release on 7 congress presentations.
← Dashboard
Nov 13, 2026 12:33 AM ET